Indications And Dose
Community-acquired pneumonia | Hospital-acquired pneumonia | Intra-abdominal infections | Complicated urinary-tract infections | Acute exacerbations of chronic obstructive pulmonary disease ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION ▶Adult: 1–2 g once daily, 2 g dose to be used for hospital-acquired pneumonia and severe cases Cellulitis | Erysipelas | Moderate diabetic foot infection | Severe diabetic foot infection | Leg ulcer infection ▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: 2 g once daily Complicated skin and soft tissue infections | Infections of bones and joints ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION ▶Adult: 2 g once daily Suspected bacterial infection in neutropenic patients ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION ▶Adult: 2–4 g daily, doses at the higher end of the recommended range used in severe cases Bacterial meningitis | Bacterial endocarditis ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION ▶Adult: 2–4 g daily, doses at the higher end of the recommended range used in severe cases ▶BY INTRAVENOUS INFUSION ▶Child 1 month–11 years (body-weight up to 50 kg): 80–100 mg/kg once daily, 100 mg/kg once daily dose should be used for bacterial endocarditis; maximum 4 g per day ▶Child 9–11 years (body-weight 50 kg and above): 2–4 g once daily, doses at the higher end of the recommended range used in severe cases ▶Child 12–17 years: 2–4 g once daily, doses at the higher end of the recommended range used in severe cases ▶BY INTRAVENOUS INJECTION ▶Child 9–11 years (body-weight 50 kg and above): 2–4 g once daily, doses at the higher end of the recommended range used in severe cases; doses of 50 mg/kg or more should be given by infusion ▶Child 12–17 years: 2–4 g once daily, doses at the higher end of the recommended range used in severe cases ▶BY DEEP INTRAMUSCULAR INJECTION ▶Child 1 month–11 years (body-weight up to 50 kg): 80–100 mg/kg daily, 100 mg/kg daily dose should be used for bacterial endocarditis; maximum 4 g per day ▶Child 9–11 years (body-weight 50 kg and above): 2–4 g daily, doses at the higher end of the recommended range used in severe cases ▶Child 12–17 years: 2–4 g daily, doses at the higher end of the recommended range used in severe cases Surgical prophylaxis ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION ▶Adult: 2 g for 1 dose, dose to be administered 30–90 minutes before procedure Uncomplicated gonorrhoea | Pelvic inflammatory disease ▶BY DEEP INTRAMUSCULAR INJECTION ▶Adult: 500 mg for 1 dose Syphilis ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION, OR BY DEEP INTRAMUSCULAR INJECTION ▶Adult: 0.5–1 g once daily for 10–14 days, dose increased to 2 g once daily for neurosyphilis Lyme disease [affecting central nervous system] ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Adult: 2 g twice daily for 21 days, alternatively 4 g once daily for 21 days Lyme arthritis | Acrodermatitis chronica atrophicans ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Adult: 2 g once daily for 28 days Lyme carditis ▶BY INTRAVENOUS INFUSION, OR BY INTRAVENOUS INJECTION ▶Adult: 2 g once daily for 21 days Prevention of secondary case of meningococcal meningitis ▶BY INTRAMUSCULAR INJECTION ▶Adult: 250 mg for 1 dose Prevention of secondary case of Haemophilus influenzae type b disease ▶BY INTRAMUSCULAR INJECTION, OR BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: 1 g daily for 2 days Acute otitis media ▶BY DEEP INTRAMUSCULAR INJECTION ▶Adult: 1–2 g for 1 dose, dose can be given for 3 days if severely ill or previous therapy failed Acute prostatitis ▶BY SLOW INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: 2 g once daily l UNLICENSED USE g Not licensed for prophylaxis of Haemophilus influenzae type b disease. l Not licensed for prophylaxis of meningococcal meningitis. ▶In adults g Dose not licensed for treatment of pelvic inflammatory disease in adults over 18 years. Ceftriaxone is used for Lyme disease affecting the central nervous system, h but the dose is not licensed for this indication.
Source pages 578, 579